Human platelet fraction arginine-vasopressin. Potential physiological role

J Clin Invest. 1987 Mar;79(3):881-7. doi: 10.1172/JCI112898.


Arginine-vasopressin (AVP) immunoreactivity (Ir) has been found to be elevated in platelet-rich plasma. PlatAVP was defined as platelet-rich plasma Ir minus platelet-poor plasma Ir (Pavp). PlatAVP, Pavp, and synthetic AVP were found to have identical retention time on high performance liquid chromatography analysis and similar mobility on thin-layer chromatography. During a standard osmotic suppression-stimulation test, Pavp increased with plasma osmolality (Posm, mosmol/kg H2O); Pavp (pg/ml) = 0.98 (Posm -274.4), r = 0.57, P less than 0.001, n = 65; but PlatAVP was not significantly correlated with Posm and remained at 5 pg/ml. This PlatAVP concentration was estimated to represent a true intraplatelet AVP concentration of 0.4 to 3.7 X 10(-9) M. Binding studies on intact human platelets demonstrated specific binding sites for [3H]AVP (n = 16; BMax = 98 +/- 30 binding sites/platelet; Kd = 0.72 +/- 0.24 nM). This in vitro affinity association constant (Kd) was close to the estimated in vivo intraplatelet AVP concentration. Measurement of PlatAVP could estimate vasopressin bound to a specific platelet receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine Vasopressin / blood*
  • Blood
  • Blood Platelets / metabolism*
  • Chromatography, High Pressure Liquid
  • Chromatography, Thin Layer
  • Diabetes Insipidus / blood
  • Female
  • Humans
  • Male
  • Osmolar Concentration
  • Receptors, Angiotensin / metabolism
  • Receptors, Vasopressin
  • Sodium Chloride
  • Water


  • Receptors, Angiotensin
  • Receptors, Vasopressin
  • Water
  • Arginine Vasopressin
  • Sodium Chloride